Ohio State Navbar

Directory

More About Dr. Abdel-Rahman


Staff photo

400 W Twelfth Ave
Rm 252N Wiseman Hall
Columbus, OH 43210

Phone: (614) 292-1396

Email: abdel-rahman.4@osu.edu

 

Current OSU Appointment

Assistant Professor, Ophthalmology

 

Biographical

Spending one third of my life and more than one half of my adult life at The Ohio State University made me a true “Buckeye” and it gives me a great pride to be a faculty in the Department of Ophthalmology and Visual Science at OSU.

After finishing medical school, pathology residency and fellowship training in Egypt, I came to OSU in the fall of 1997 to pursue my graduate education which I finished in 2002 with a PhD in Pathology. After a short post-doc at University of Texas MD Anderson Cancer Center, I came back to OSU for another post-doc at the department of ophthalmology then a clinical fellowship in cancer genetics. I went back to Egypt in 2006 where I worked as attending pathologist at the National Liver Institute Menoufiya University, then I was recruited back to OSU in 2009. Since then, I have been on the faculty of the department of ophthalmology and as an adjunct faculty at the division of human genetics. In late 2011, I lost my late wife in a tragic accident. I also suffered physical injuries. This tragedy impacted my productivity significantly. I also had to take time off to care for my children and to heal. Upon returning, I was able to resume my research projects and successfully compete for NIH support.
Since I came to OSU as a faculty, I believe that I exhibited sustained evidence of excellence in the discovery and dissemination of new knowledge. I have demonstrated national and international level of significance and recognition of scholarship to warrant my promotion to Associate Professor. The following are some of my accomplishments:

A.&emspScholarship:

I.&emspResearch on BAP1-Tumor Predisposition Syndrome (TPDS):
-&emspIn 2011 we were one of three independent research groups to characterize a novel hereditary cancer predisposition syndrome caused by germline mutation in the BAP1 gene (OMIM # 614327). This new hereditary cancer syndrome is associated with multiple different cancers including uveal melanoma, cutaneous melanoma, mesothelioma, atypical Spitz nevi, renal cell carcinoma and potentially other cancers.
-&emspOur manuscript was the first to describe the multi-cancer aspect of the BAP1-TPDS. It has been selected as the JMG editors’ choice and it made publicly available. Since its publication in 2011 it has been cited 183 times. The article is cited by OMIM as one of the four references describing the BAP1-TPDS. In addition, we published several follow up manuscripts expanding the clinical phenotype of the syndrome and describing the proposed clinical management. They are also well cited.
-&emspWe prepared a clinical guideline for diagnosis and management of the BAP1-TPDS syndrome for the NCBI online resource GeneReviews. Our manuscript has been accepted for publication and will appear online October, 2016. As described on their website, “GeneReviews is an international point-of-care resource for clinicians that provide clinically relevant and medically actionable information for inherited conditions. It covers diagnosis, management, and genetic counseling for patients and their families. It currently has 669 chapters. Each chapter is written by one or more experts on the specific condition or disease and goes through a rigorous editing and peer review process”.
-&emspOur expertise at OSU in BAP1 is well recognized nationally and internationally. So far I have been invited to review four international grants on BAP1, I completed 3 and declined one for lack of time and reviewed 8 manuscripts on BAP1 (including journals such as New England J of Medicine, Nature review cancer and PLOS genetics). I have been invited to give one local, two national and three international guest lectures on the topic. My co-worker Robert Pilarski has been invited as a plenary speaker on the BAP1-TPDS at the National Genetic Counselor Society meeting and he was also invited to give genetic counselor education lectures at NIH and NCI on the syndrome. My co-worker Colleen Cebulla has been invited to give talks on the topic to the retinal society.
-&emspBased on our well recognized expertise in BAP1 and hereditary predisposition to uveal melanoma, we have received patients' referral from 27 different states in the US with a 44% accrual from outside OSU. We also received patients’ referral and consultation requests from several foreign countries including Italy, Canada, Belgium, UK, Ireland, Australia, Brazil, Netherlands and Jordan. In addition, many patients from outside Ohio travel to our program for counseling and guidance.
-&emspWe are currently leading the effort to establish an international registry for BAP1-TPDS patients and we developed a redcap database questionnaire.
-&emspOur expertise in BAP1 sequencing is also well recognized, we are a referral research laboratory for patients with clinical features suggestive of the syndrome. Also I have received several requests from academic and clinical laboratories to assist and troubleshoot the development of their sequencing assays.

II.&emspResearch on Hereditary Predisposition to Uveal Melanoma:
-&emspWe have changed the very limited view of hereditary predisposition to uveal melanoma from being a rare familial cancer (less than1% of all patients), to a more common 12% of uveal melanoma population with a heterogeneous cancer phenotype.
-&emspBased on our strong national and international reputation, we accrued 32 familial uveal melanoma patients/families (there are only 115 patients reported worldwide). This was well recognized by the reviewers of my funded R21 NCI grant who noted that our patient cohort is one of the largest for familial uveal melanoma collected in the world. In addition, we accrued more than 150 uveal melanoma patients with strong personal and family history of cancers. This includes 20 patients referred to our program by Cleveland Clinic. These large familial uveal melanoma and high-risk hereditary cancer cohorts are the foundation for a multi-PI R01 grant that we submitted to the NCI recently.
-&emspI built a multi-institutional consortium that includes OSU, Cleveland Clinic and Liverpool Ocular Oncology Group. The later is the third largest ocular oncology referral program in Europe. This multi-institutional consortium that has already accrued >1200 uveal melanoma patients with an accrual goal of >1000 additional patients in 3 years was instrumental in our recent multi-PI NCI R01 grant submission.
-&emspOur NCI funded R21 award helped with the characterization of additional hereditary cancer predisposition genes. I’ll be presenting one of these genes ATAD5 in the upcoming American Society of Human Genetic Meeting and I submitted an NCI R03 grant to further study that gene in uveal melanoma.
-&emspWe recently identified variants in pigmentary gene HERC2 that control eye color—as risk alleles for uveal melanoma. The discovery has been recognized in multiple media outlet and in ASCO and PLOS communications. This discovery provide a paradigm shift in the field since uveal melanoma is not linked to UV exposure suggesting additional molecular mechanisms for its carcinogenics role. This discovery is the basis of a pelotonia grant that we recently submitted and to an upcoming NCI R21 that we are planning to submit in response to the NCI provocative questions.

III.&emspResearch on Somatic Genetic Alterations in Uveal Melanoma
-&emspI served as co-investigator for the NIH Cancer Genome Atlas (TCGA) Project for uveal melanoma (UM). The well annotated biorepository that we developed was one of 6 centers in the world to contribute uveal melanoma tissues and matching normal samples to the TCGA.
-&emspI was member of the following subcommittees: the Pathology Expert panel, the Analysis Group and the Writing Group for the uveal melanoma TCGA. I played a critical role in the reanalysis of BAP1 gene alterations and contributed to writing the UM-TCGA marker paper which has been submitted to Cancer Cell.
-&emspI am serving as co-investigator for multicenter adjuvant clinical trial for high-risk uveal melanoma (grants.gov NCT02223819, OSU 14129 Olencki (PI) “Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy”). The trial has opened September 2016. One of my papers (MET oncogene inhibition as a potential target of therapy for uveal melanomas, IOVS 2010: 51,7: 3333-9) provided important preliminary data for this trial.

IV.&emspResearch on Ocular and Tumor Angiogenesis and anti-angiogenic agents
-&emspWe had two published manuscripts on anti-angiogenic agents and an ongoing project to study anti-angiogenic agents from natural product. The later is funded by an award from the Ohio Lions Eye Research Foundation.
-&emspBased on my expertise in angiogenesis studies I'll serve as a co-Investigator on an NCI R01 grant on the Deciphering the non-pigmentary phenotypic impacts of OCA2 variants.
V.&emspResearch on Hepatocellular Carcinoma
-&emspThis is part of my global outreach effort to address one of the growing cancer problems in my native country Egypt and also in the US.
-&emspAs part of healing process after my tragedy in 2011, I lead the efforts to establish a biorepository and research laboratory at National Liver Institute, Menoufiya University. The political turmoil in the country slowed our progress significantly but we were able to have the project up and running in 2013.
-&emspDuring the last 1.5 years they have been able to accrue a large cohort of HCC patients and controls including more than 1200 serum/plasma/DNA samples from HCC patients. This cohort is the basis of a recent collaborative US/Egyptian grant that we submitted to the USAID. Also through utilizing these resources I collaborated with Dr. Christopher Cross from College of pharmacy, OSU to submit a Pelotonia grant to study HCC and I am working with him on an upcoming R21 NCI grant submission.
-&emspI have been active member of the OSU liver Cancer research interest group and we are currently developing IRB approved retrospective and prospective biorepositories for patients with HCC from OSU.
-&emspOur preliminary work on HCC has been recently selected as a top score poster at the International Liver Cancer Association meeting in 2016.

B. Teaching and Mentoring:
- Since the start of my faculty appointment at OSU in 2009, I mentored seven undergraduate students Benjamin Christopher, Omar Saqr, Samidha Dutta, Tiffany Wang, Karan Rai and Timothy Grosel. I also mentored the summer research projects of three medical students Benjamin Romney, Kareem Saleh and Muneeb Rehman. Currently I am mentoring one undergraduate student Khara Walker who is funded through a Pelotonia award.
- I am on the advising committee of several graduate students from Egypt. Two of my graduate students (Ahmad Agour and Asmaa Abdel-Maksood) obtained scholarships and came to OSU for part of their training. I currently have a doctorate degree student Laila Farid on a 1-year joint supervision program funded through the Egypt Mission Department.
- At OSU, I taught pathology and genetics to ophthalmology residents in 2012 and graduate students in Genetic Counseling Master Program in 2015.
- As part of global outreach and education, I gave several seminars and workshops on genetics, molecular genetics at the Menoufiya University and Children Cancer Hospital in Egypt.
- I’ll be teaching molecular genetics to pathology residents and fellow in Egypt as part of education training program for the UK Membership of Royal College of Pathologists’ examination (MRCPath).

C. Service:
- Director of ocular oncology research laboratory, department of ophthalmology, OSU (01/2011-present).
- Director of ophthalmic pathology education for ophthalmology residents (2012)
- Member of medical retina fellowship selection committee (2014-present)
- Founder and Director of National Liver Institute, Sustainable Sciences Institute Collaborative Research Laboratory (NLISSICRC) Egypt (09/2011-08/2012). Obtained a $100,000 grant from the SSI to establish a biorepository and research laboratory which has been continuously renewed. Carried out training (in Egypt and at OSU) for young researcher and established a biorepository.
- Scientific advisor and consultant of NLISSICRC, Egypt. (09/2012-present). Maintained fund and supervised scientific progress of the center.
- Grants reviewer for Research Counsels UK, British Lung Foundation UK and North West Cancer Research, Liverpool, UK.
- Ad-hoc reviewer for Cancer Research, Molecular Cancer Therapy, Clinical Cancer Research, Investigative Ophthalmology and Visual Science, British Journal of Cancer, Melanoma Research, British Journal of Ophthalmology, Nature Reviews Cancer, PLOS one, PLOS genetics and New England Journal of Medicine.
- Scientific advisor for Egyptian Student Association at the OSU (2014-2015).
- TCGA project: member of the Analysis Working Group, Pathology Expert Group and Manuscript writing group (2014-2016)
- Non compensated spoke person for American Cancer Society and Melanoma Know More Foundations
- Co-course Director: Havener Eye Institute 57th Annual Post graduate Symposium in Ophthalmology, The Ohio State University, Columbus, Ohio, United States (2014).

Clinical Interest

Anatomic Pathology

Clinical Medical Genetics

Academic Advising

I am a strong believer of investing in undergraduate students' research, especially for highly talented candidates. My strategy is to select one or two students/year who I train and give independent research projects. I try to limit the number of students rotating in the lab at any time to maximum of two students so I can have sufficient time for mentoring. Although working with undergraduate students is challenging, I find it highly rewarding.

In addition to the long term projects carried out by selected undergraduate students, I accept other undergraduate and medical students for shorter rotations depending on their expertise and research interests.

Since the start of my faculty appointment at OSU in 2009, I mentored six undergraduate students: Benjamin Christopher, Omar Saqr, Samidha Dutta, Tiffany Wang, Karan Rai and Timothy Grosel . I also mentored three medical students research projects: Benjamin Romney, Kareem Saleh and Muneeb Rehman. Currently I am mentoring one undergraduate student Khara Walker, who is funded through a Pelotonia award.

I have been on the advising committee of several graduate students in Egypt. Two of my graduate students from Egypt (Ahmad Agour and Asmaa Abdel-Maksood) obtained scholarships and came to OSU for part of their training. I currently have a doctorate degree student Laila Farid on joint supervision program funded through the Egypt Mission Department.

Noteworthy Graduate Narrative

Eman Adbelsamee MD is currently a junior faculty (lecturer) at the hepatology department, Menoufiya University.

Samira Abdelwehab MD, is currently a junior faculty (lecturer) at pediatric hepatology program Menoufiya University.

Master/Graduate Advising

I currently mentor 5 PhD students from Egypt (1 from Menoufiya University, 1 from Cairo University, 1 from Ain Shams University and 2 from Sadat University).

Two of them (Ahmed A. Agour, MD, MSc and Asmaa Abdel-Maksoud Mosbeh, MSc) obtained scholarships and came to my laboratory at OSU for 3 months to carry out part of their training.

One of them (Laila Farid,MD) is currently in my lab on a Doctorate Joint-Supervision Scholarship funded through the Egyptian Mission Department (1-2 yrs based on available funds).

Continuing Education, Extension, and Other Courses Taught

I’ll be teaching molecular genetics to pathology residents and fellows in Egypt as part of education training program for the UK Membership of Royal College of Pathologists’ examination (MRCPath). I have been selected by the organizing committee for my expertise in the field. This will be an annual training program.

I also carried out workshops at several universities in Egypt on the basics of genetics, molecular genetics and cell biology.

Academic Advising

2014 Thomas Grosel, The Ohio State University. Graduated 2016.
2015 Laila Magid, Ain Shams University. Graduated 0.
2016 Khara Waler, The Ohio State University. Graduated 0.
2013 Omar Saqr, The Ohio State University. Graduated 2013. Study of germline BAP1 and VHL mutation in uveal melanoma patients with personal and or family history of renal cell carcinoma
2014 Kareem Saleh, The Ohio State University. Graduated 0. Molecular Genetics of Choroidal Nevi
2014 Muneeb Rehman, The Ohio State University. Graduated 0. Study of a Novel Candidate Gene for Hereditary Predisposition to Uveal Melanoma
2013 - 2015 Elaine M, The Ohio State University. Graduated 2015. Analysis of BAP1 germline gene mutation in young uveal melanoma patients
2014 - 2015 Karan Rai, The Ohio State University. Graduated 2015. Comprehensive Review of BAP1 Tumor Predisposition Syndrome
2015 - 2016 Karan Rai, The Ohio State University. Graduated 0.
 

Books

Study of hepatic histopathological changes in chronic viral hepatitis with and without schistosomiasis

Molecular genetic profiling of low-grade gliomas: towards a molecular genetic classification

Malignant Melanoma of the Uvea, A symposium

 

Licenses

1992 - present Unrestricted Medical License: Egyptian Ministry of Health
1992 - present General Medical Practitioner: Egyptian Ministry of Health
1998 - present ECFMG: Educational Commission for Foreign Medical Graduates
2007 - present Consultant Histopathology: Egyptian Medical Syndicate
2007 - present Histopathology Consultant: Egyptian Ministry of Health
2009 - present Unrestricted Medical License: State Medical Board of Ohio
 

Chapters in Books

Enucleation for Choroidal Melanomas

BAP1-Tumor Predispostion Syndrome

 

Clinical Services

07/01/2007 Pathology Practice (Menoufiya, Egypt)

Conferences

Derivative Yt(Y;1)(q12;q12) associated with myelodysplasia; a case report and review

Amplification and over-expression of PI3KC2B, a candidate oncogene in 1q32, in a case with low-grade glioma

Combination of comparative genomic hybridization (CGH) and gene expression profiling differentiates pilocytic astrocytomas from other low-grade gliomas and identifies novel biomarkers

Molecular genetic profiling of uveal melanoma reveals clinically significant molecular subclasses

Expression of vascular endothelial growth factor (VEGF) in uveal melanoma is independent of the copy number of 6p21 region

Anti-angiogenic effect of Linomide analogue

Molecular genetic profiling identify the involvement of different molecular pathways in the pathogenesis of aggressive uveal and cutaneous melanomas

Expression of vascular endothelial growth factor (VEGF) in uveal melanoma is independent of the copy number of 6p21 region

High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma

High frequency of cMET over-expression in uveal melanoma through altered gene regulation rather than mutation and amplification of the cMET gene

Higher Colon Cancer Risk in Uveal Melanoma Patients and Their Relatives Compared to General Population

Alterations in phosphatase and tensin homolog (PTEN) tumor suppressor gene in Egyptian patients with hepatocellular carcinoma

A Complex Role of NBS1 Gene in the Tumorogenesis of Uveal Melanomas

MET oncogene inhibition as a potential target for therapy of uveal melanomas.

Antineoplastic Activity of Selected Group of Medicinal Plants Against Uveal Melanomas

Metastasis in Small Uveal Melanomas

Cancer Family History Characterization and Candidate Gene Testing in an Unselected Cohort of 121 Patients With Uveal Melanoma

Long Term Survival in Metastatic Uveal Melanoma

Biological activity and molecular mechanism of action of gallocatechin 5-O-gallate and epigallocatechin 3-O-gallate on uveal melanoma

Molecular Genetic Testing in Uveal Melanoma: An Examination of the Practice Patterns of North American Ocular Oncologists

Molecular Genetic Testing of Uveal Melanoma from Routinely Processed and Stained Cytology Specimens

Lack of MAPK activation in significant number of uveal melanomas with somatic mutation in GNAQ and GNA11

Monosomy 3 status of metastatic uveal melanoma is associated with rapidly aggressive, therapy-resistant tumors

Antiangiogenic plant extracts for potential treatment of ocular neovascularization

The Role of Programmed Cell Death 4 in the Pathogenesis of Uveal Melanoma.

Candidate Gene Testing In Uveal Melanoma Patients With Relative High-risk For Hereditary Cancer Predisposition

Retinal MMP-12, MMP-13, TIMP-1, and TIMP-2 Expression in Murine Experimental Retinal Detachment

Cyclooxygenase-2 (COX-2) expression in primary uveal melanoma and the potential role for adjuvant treatment with COX-2 inhibitors

Study of germline BAP1 and VHL mutation in uveal melanoma patients with personal and or family history of renal cell carcinoma

Two novel germline BAP1 mutations in two unrelated families with features of the BAP1 Tumor Predisposition Syndrome.

Lack of BAP1 germline gene mutation in patients with early onset uveal melanoma

Up-Regulation of VEGF by Hyaluronic Acid in Microglia

Germline epigenetic inactivation of BAP1 in a subset of patients with uveal melanoma.

Whole genome exome sequencing to identify novel candidates for hereditary predisposition to UM uveal melanoma.

Germline BAP1 mutations misreported as somatic based on tumor-only testing.

The identification of novel genetic risk loci in uveal melanoma.

Genetic alterations in commonly utilized hepatocellular carcinoma cell lines, evidence of bias toward HBV background

Mechanisms of somatic biallelic inactivation of BAP1 in uveal melanoma

 

Degrees

1990 M.D., Cairo University

1996 M.S., Menoufiya University

2002 Ph.D., The Ohio State University

 

Editorial Activities

2008 - present Cancer Research
2009 - present Investigatve Ophthalmology and Visual Science
2009 - present Clinical Cancer Research
2011 - present Familial Cancer
2012 - present Dove Medical Publications
2012 - present Nature Review Cancer
2013 - present Molecular Cancer Research
2014 - present JAMA Ophthalmology
2016 - present British Jounral of Ophthalmology
 

Honors

2000 Loes Jones Endowment for cancer research fellowship award. Comprehensive Cancer Center.
2001 Travel Fellowship. 10th International Congress of Human Genetics.
2010 Junior Investigator Award. Ocular Melanoma Foundation.
 

Journal Articles

 

Reference Works

October 2000 Abdel-Rahman, MH; Glasure, CE; Caligiuri, MA; Theil, KS."Der(Y)t(Y;1)(q12;q12) associated with myelodysplasia: Case report and review of the literature." . : 72-72
October 2008 Abdel-Rahman, M,H; Pilarski, R; Ezzat, S; LaJeunesse; Davidorf, F, H.."Hereditary cancer predisposition in a subset of uveal melanoma patients and their family members" .
January 2010 Abdel-Rahman, MH, B. Christopher B, M. Faramawi M, Said-Ahmed K, Cole C, McFaddin A, Ray-Chaudhury A, Heerema N, Davidorf F.."Frequency, Molecular Pathology and Clinical Significance of Partial Chromosome 3 Alterations in Uveal Melanoma." .
November 2010 Abdel-Rahman,M,H; Christopher,B,N; Faramawi,M,F; Said-Ahmed,K; Cole,C; McFaddin,A; Ray-Chaudhury,A; Heerema,N; Davidorf,F,H.."Frequency, Molecular Pathology and Clinical Significance of Partial Chromosome 3 Alterations in Uveal Melanoma" .
January 2011 Salem MM, Davidorf FH, Abdel-Rahman MH.."Biological activity and molecular mechanism of action of gallocatechin 5-O-gallate and epigallocatechin 3-O-gallate on uveal melanoma." .
April 2011 Abdel-Rahman MH, Boru G, Cebulla CM, Christopher B, Massengill JB, Davidorf F.."Lack of MAPK activation in significant number of uveal melanomas with somatic mutation in GNAQ and GNA11" .
January 2011 Salem MM, Vaidaya N, Said-Ahmed K, Massengill JB, El-Garf I, Davidorf FH, Abdel-Rahman MH.."Antiangiogenic plant extracts for potential treatment of ocular neovascularization." .
October 2011 Benes, S, C; Abdel-Rahman, M,H; Dosunmu, E; Craig, E.."Somatic Mutation of GNA11 in an Optic Nerve Sheath Dural Melanoma" .
November 2012 Pilarski, R; Cebulla, C, M; Rich, T; Strong, L; Abdel-Rahman, M, H.."Germline BAP1 mutation - Additional case report and expanding clinical phenotype" .
October 2013 Pilarski, R; Cebulla, C, M; Saqr, O; Rai, K; Massengill, J, B; Davidorf, F, H; Abdel-Rahman, M, H.."Germline BAP1 mutations in uveal melanoma patients with a personal and/or family history of renal cell carcinoma." . : 3443F
October 2013 Pilarski, R; Cebulla, C,M; Saqr, O,H; Rai, K; Massengill, J,B; Davidorf, F,H; Abdel-Rahman, M,H.."Study of germline BAP1 and VHL mutation in uveal melanoma patients with personal and or family history of renal cell carcinoma" . : 3443F
October 2014 Abdel-Rahman, M, H; Hedges, D; Pilarski, R; Boru, G; Massengill, J, B; Rai, K; Davidorf, F,H; Cebulla, C,M.."Whole genome exome sequencing to identify novel candidates for hereditary predisposition to UM uveal melanoma" . : 3484T
October 2014 Pilarski, R; Boru, G; Saqr, O, H; Rai, K; Massengill, J, B; Cebulla, C, M; Abdel-Rahman, M,H.."Germline epigenetic inactivation of BAP1 in a subset of patients with uveal melanoma" . : 3485T
October 2014 Cebulla, C, M; Pilarski, R; Rai, K; Massengill, J,B; Boru, G; Davidorf, F, H; Abdel-Rahman, M,H.."Two novel germline BAP1 mutations in two unrelated families with features of the BAP1 Tumor Predisposition Syndrome" . : 3485S
October 2015 Abdel-Rahman, M, H; Rai, K; Pilarski, R; Davidorf, F, H; Cebulla, C,M.."Germline BAP1 mutations misreported as somatic based on tumor-only testing" . : 2767

Presentations

Molecular genetic profiling of uveal melanoma reveals clinically significant molecular subclasses

Expression profiling identifies similar expression pattern of uveal melanomas with chromosome 3 isodiosmy to those with monosomy 3

The Practice of Clinical Cancer Genetics

Uveal Melanoma, what can we learn from the other rare eye tumor

Hereditary predisposition to uveal melanoma

What can we learn from the genetics of uveal (ocular) melanoma

Genetics and Pathology of Retinoblastoma

Clinical Cancer Genetics, The Ophthalmology Prespective

Hereditary predisposition to uveal melanoma, not just BAP1

Lessons learned from the genetics of a rare eye tumor

Clinical cancer genetics; ophthalmology perspective

Comprehensive review of BAP1 tumor predisposition syndrome with report of three new cases

BAP1 Tumor Predisposition Syndrome literature review and report of two cases

Advances in Genetics and Pathology of Uveal Melanoma

 

Professional Activities

present Denman Undergraduate research forum 2016. The Ohio State University.
present Denman Undergraduate research forum 2015. The Ohio State University.
present Denman Undergraduate research forum 2014. The Ohio State University.
2009 - present Denman Undergraduate Research Forum. The Ohio State University.
2010 - present OSUMC Research Day. College of Medicine, The Ohio State University.
- 2009 Denman Undergraduate Research Forum. The Ohio State University.
- 2010 OSUMC research day. College of Medicine, The Ohio State University.
- 2010 Denman Undergraduate research forum. The Ohio State University.
- 2010 Invited speaker. Children's Cancer Hospital of Egypt.
- 2010 Educational workshop. Children's Cancer Hospital of Egypt.
- 2011 Denman Undergadutae Research Forum 2011. The Ohio State University.
- 2011 Non compensated spokesperson. American Cancer Society.
- 2011 OSUMC research day 2013. College of Medicine, The Ohio State University.
2011 - 2012 Establishing a bio-repository research laboratory and program in molecular genetics in Egypt. Sustainable Sciences Institute & Menoufiya University.
2015 Tumor Cancer Genome Atlas Uveal Melanoma. Pathology Expert Panel. National Cancer Institute.
2014 - 2016 Tumor Cancer Genome Atlas Uveal Melanoma Analysis Working Group. National Cancer Institute.
 

Unpublished Works

Heterogeneity in MAPK activation and GNAQ and GNA11 somatic mutations in uveal melanomas, potential impact for therapy

The Role of Programmed Cell Death 4 in the Pathogenesis of Uveal Melanoma

Integrative Analysis Identifies Distinct Molecular Subsets within BAP1-Aberrant Poor-1 Prognosis Uveal Melanoma

Integrative Analysis Identifies Distinct Molecular Subsets within BAP1-Aberrant Poor-1 Prognosis Uveal Melanoma

Heterogeneity in MAPK activation and GNAQ and GNA11 somatic mutations in uveal melanomas, potential impact for therapy

The Role of Programmed Cell Death 4 in the Pathogenesis of Uveal Melanoma